Hypoxia-induced upregulation of SK3 together with the EMT transcription factor Zeb1 in prostate cancer cells is promoted by the anti-androgen Enzalutamide, used for the treatment of castration-resistant prostate cancer [331,377]. Here, ZEB1 is linked to prostate carcinoma.